REX1BD

Across TCGA pan-cancer cohorts, REX1BD RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of REX1BD’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where REX1BD RNA is more highly expressed in tumor relative to normal tissue. In most cancer types REX1BD is over-expressed in tumor.

COAD, HNSC, and KIRC are the cancer types where REX1BD tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in REX1BD RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	All	+1.454	<.001	11	view →
HNSC	Male	III,IV	+0.930	<.001	10	view →
KIRC	Male	III,IV	+0.620	<.001	9	view →
STAD	All	II,III,IV	+0.648	<.001	8	view →
LIHC	Female	All	+0.925	<.001	6	view →
READ	All	All	+1.008	.004	3	view →
ESCA	All	All	+0.922	<.001	3	view →
LUSC	Male	All	+0.440	.001	3	view →
THCA	All	All	+0.317	.015	3	view →
CHOL	All	All	+0.705	.004	2	view →
BLCA	All	All	+0.417	.018	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

REX1BD–COAD

Open the COAD breakdown →